VTU Technology and RCT Announce Partnership
News Dec 12, 2014
VTU Technology and Research Corporation Technologies (RCT) have announced that they have entered into a development and commercialization agreement for VTU to combine both companies´ Pichia pastoris protein production technologies.
Pichia GlycoSwitch® - a new expression system for the production of glycoproteins with human-like glycosylation patterns - and VTU´s yield enhancing Pichia pastoris expression platform are now available in one package from VTU.
This unique combination of technologies acting synergistically is of great benefit for customers as it leads to a high performance production platform for recombinant glycoproteins with superior product yields and uniform Man5 - or other human-like glycoforms.
Under the terms of the agreement, RCT grants VTU Technology access to RCT´s Pichia GlycoSwitch® expression system for combination with VTU´s in-house high-yielding Pichia platform featuring different proprietary technologies such as AOX1 promoter libraries suited for both methanol-induced and methanol-free production. VTU Technology is now offering the combined technology suite as part of the company´s expression strain and corresponding bioprocess development contract services portfolio.
“We are delighted to offer Pichia GlycoSwitch® engineered with our broad portfolio of Pichia tools in this partnership with RCT and I am convinced that our yield enhancing technologies will give GlycoSwitch® an exciting extra edge for the production of glycoproteins with Man5 - or other human-like glycoforms”, states Thomas Purkarthofer, Ph.D., Head of Business Development of VTU Technology.
“Our partnership with VTU Technology brings together two technologies that will enable customers to uniquely tailor the glycosylation of their target protein and explore new biological functions. We are looking forward to working with VTU Technology to expand the potential of proteins manufactured in Pichia GlycoSwitch®”, states Kurt R. Gehlsen, Ph.D., Vice President and CSO of Research Corporation Technologies, Inc.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.